AcelRx upgraded to Buy from Neutral at H.C. Wainwright

H.C. Wainwright analyst Ed Arce upgraded AcelRx to Buy from Neutral with an $8 price target. The analyst sees a “significant and readily accessible market opportunity” with the company’s lead asset, Niyad. With the divestiture of Dsuvia completed in April, and the resubmission of an Emergency Use Authorization application for Niyad later that same month, AcelRx is a “renewed company with a distinct profile,” the analyst tells investors in a research note. The firm views Niyad as “derisked,” with a substantial near-term catalyst and a significant and accessible market opportunity.